FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1171-1173 April 11, 2002 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: The study by in 't Veld et al. (Nov. 22 issue)¹ on the prevention of Alzheimer's disease with nonsteroidal antiinflammatory drugs (NSAIDs) includes no mortality data. It is entirely possible that patients who received long-term treatment with NSAIDs were dying sooner from the complications. One may then underestimate the risk of Alzheimer's disease, giving a false positive result. There are also no data on morbidity. The small group of patients receiving NSAIDs for more than 24 months was the only group with a statistically significant reduction in the risk of Alzheimer's disease. It may be inappropriate to . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Szekely, C. A., Breitner, J.C.S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., Zandi, P. P. (2008). NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type. Neurology 70: 17-24 [Abstract] [Full Text]